(Q36334896)

13 August 2017

1 reference

title

Molecularly targeted therapy in renal cell carcinoma (English)

1 reference

13 August 2017

1

W Kimryn Rathmell

1 reference

13 August 2017

Tricia M Wright

2

1 reference

PubMed ID

16336094

13 August 2017

Brian I Rini

series ordinal

3

1 reference

13 August 2017

1 December 2005

1 reference

Expert Review of Anticancer Therapy

13 August 2017

1 reference

13 August 2017

5

1 reference

13 August 2017

6

1 reference

13 August 2017

1031-1040

1 reference

Mutations of the VHL tumour suppressor gene in renal carcinoma

13 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

TSC2 regulates VEGF through mTOR-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Bevacizumab for patients with metastatic renal cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Ras effectors and their role in mitogenesis and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

21 January 2018

A Ras by any other name

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Discovery of a novel Raf kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Rapamycin is an effective inhibitor of human renal cancer metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.6.1031

10.1586/14737140.5.6.1031

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16336094